Metabasis Therapeutics received promising results from its Phase IIa clinical trial of MB07803 for the treatment of Type 2 diabetes.
The drug was safe and well tolerated and met the study’s primary efficacy endpoint of a significant reduction in fasting plasma glucose (FPG). Administration of the drug at 200 mg resulted in a placebo-adjusted reduction in FPG from baseline of -28.9 mg/dL at day 28.
The drug regulates excess glucose production in the liver by inhibiting a key enzyme in the gluconeogenesis pathway. If approved, the product could serve as an alternative for diabetes patients who are unable to tolerate the current first-line therapy, metformin, Metabasis said.